BamSEC and AlphaSense Join Forces
Learn More

Tarsus Pharmaceuticals Inc. – Material Contracts

NASDAQ: TARS    
Share price (5/29/26): $59.40    
Market cap (5/29/26): $2.556 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 10-Q 5 pages Material contract
12/34/56
EX-10.27
from 10-K 19 pages Material contract
12/34/56
EX-10.26
from 10-K 6 pages Material contract
12/34/56
EX-10.25
from 10-K 17 pages Material contract
12/34/56
EX-10.24
from 10-K 3 pages Material contract
12/34/56
EX-10.1
from 10-Q 171 pages Material contract
12/34/56
EX-10.1#
from 10-Q 18 pages Material contract
12/34/56
EX-10.19
from 10-K 7 pages Material contract
12/34/56
EX-10.2
from 10-Q 8 pages Material contract
12/34/56
EX-10.1
from 10-Q 18 pages Separation Agreement
12/34/56
EX-10.18
from 10-K 8 pages Material contract
12/34/56
EX-10.2
from 10-Q 29 pages Material contract
12/34/56
EX-10.1
from 10-Q 28 pages Material contract
12/34/56
EX-10.2
from 10-Q 9 pages Consulting Agreement, Dated August 1, 2020, Between the Registrant and Elizabeth Yeu-Lin, M.D., as Amended
12/34/56
EX-10.1
from 10-Q 48 pages Certain Identified Information Has Been Omitted From This Document Because It Is Both Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed, and Has Been Marked With “[***]” to Indicate Where Omissions Have Been Made. Development and License Agreement
12/34/56
EX-10.15
from S-1/A 9 pages Tarsus Pharmaceuticals, Inc. Management Cash Incentive Plan
12/34/56
EX-10.12
from S-1/A 26 pages Certain Identified Information Has Been Omitted From This Document Because It Is Both Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed, and Has Been Marked With “[***]” to Indicate Where Omissions Have Been Made. License Agreement
12/34/56
EX-10.11
from S-1/A 4 pages Certain Identified Information Has Been Omitted From This Document Because It Is Both Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed, and Has Been Marked With “[***]” to Indicate Where Omissions Have Been Made
12/34/56
EX-10.10
from S-1/A 25 pages Certain Identified Information Has Been Omitted From This Document Because It Is Both Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed, and Has Been Marked With “[***]” to Indicate Where Omissions Have Been Made. License Agreement
12/34/56
EX-10.5
from S-1/A 5 pages Tarsus Pharmaceuticals, Inc. October 8, 2020
12/34/56